Clinical trials: Malignant Ascites
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites.
- Trial name
- NCT00182754
- Testing
- octreotide acetate
- Where
- 122 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignant Pleural Effusion, Malignant Ascites
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.
- Trial name
- NCT01327235
- Testing
- Endostar, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Malignant Ascites Due to Epithelial Carcinoma
Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
This phase II single arm, open-label study investigate the safety of a second cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS…
- Trial name
- SECIMAS (NCT01065246)
- Testing
- catumaxomab
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Neovii Biotech
Ascites
Trial of Sunitinib for Refractory Malignant Ascites
The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.
- Trial name
- NCT00796861
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Milton S. Hershey Medical Center
Malignant Ascites
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
Treatment of malignant ascites with the alfapump offers a new treatment option for this patient group. So far, there is no systematic analysis of patients with this indication available in the literature.
- Trial name
- NCT03200106
- Testing
- Alfapump
- Where
- 3 sites in Germany, Switzerland and 1 more
- Volunteers
- 17 people
- Sponsor
- Sequana Medical N.V.
Malignant Ascites
A Study of Bevacizumab to Prevent Malignant Ascites
The purpose of this study is to determine the effectiveness of using Bevacizumab in the prevention of recurrent malignant ascites. Ascites is a debilitating and unpleasant complication of several types of cancer.
- Trial name
- NCT00908219
- Testing
- Bevacizumab
- Where
- 3 sites in United States
- Sponsor
- Baylor College of Medicine
Pleural Effusion, Ascites
Investigating Signal Change in Malignant and Non-malignant Pleural Effusions and asCitic Fluid Using fTiR Analysis
Lung cancer is a common cancer, associated with a high mortality rate. Pleural effusions are common in lung cancer, developing in up to 40% of patients.
- Trial name
- SPECTRA (NCT04533854)
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Gastric Cancer, Stomach Neoplasms
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites
- Trial name
- NCT03475615
- Testing
- Oxaliplatin, Paclitaxel, S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
- Where
- China
- Volunteers
- 215 people
- Sponsor
- Fudan University
Cirrhosis, Ascites Hepatic
PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small volume fluid drainage at home. The treatment may improve the management of ascites and have a beneficial effect on the quality of life.
- Conditions
- Cirrhosis, Ascites Hepatic, Ascites (Non-Malignant)
- Trial name
- PETRA (NCT03027635)
- Testing
- PleurX, peritoneal tunnelated catheter, Large Volume Paracentesis, Ciprofloxacin 500Mg Tablet
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Nina Kimer
Lung Cancer, Breast Cancer
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.
- Conditions
- Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06413212
- Testing
- Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Liu Huang
Refractory Malignant Ascites
Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
Assessment of effectiveness, safety and local immune activation of Oncolytic Viruses H101 in patients with refractory malignant ascites.
- Trial name
- NCT04771676
- Testing
- Oncorine (H101)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Malignant Ascites
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles…
- Trial name
- SIM0388-101 (NCT07007988)
- Testing
- SIM0388
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Pleural Effusion, Malignant
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
- Trial name
- NCT05268172
- Testing
- IFN-γ and CIK cells, Tcm cells or CAR T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Refractory Malignant Ascites
Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
The refractory malignant ascites is a complication of advanced stages of many cancer types. It is characterized clinically by abdominal pressure sensation, shortness of breath and pelvic pain.
- Trial name
- BEVASCITE (NCT02891369)
- Testing
- No intervention. Descriptive study
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Malignant Ascites
Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Malignant ascites leads to significant morbidity in patients with terminal cancer. Paracentesis can provide relief, but repeat hospital visits, pain, and short duration of relief after paracentesis are detrimental to quality of…
- Trial name
- NCT02477657
- Testing
- Paracentesis, Tunneled Intraperitoneal Drain (IPD), Peritoneal-Venous shunts (PVS)
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Cancer
Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells.
- Trial name
- NCT00265863
- Testing
- mitomycin C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota